# A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC

Source: https://onco.cc/trials/nct05246514/  
OnCo record `nct05246514` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Trastuzumab deruxtecan in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC is a phase 2 interventional study registered as NCT05246514 by AstraZeneca, with 72 participants enrolled, started 2022-07-13 and due to reach its primary completion in 2024-11-04. Interventions recorded: Trastuzumab deruxtecan. Conditions listed: HER2-mutant Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2024; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: DESTINY-Lung05
- Tags: ctgov-ingest
- Registry id: NCT05246514
- Phase: 2
- Setting: An Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for Patients With HER2-mutant Metastatic NSCLC Who Have Disease Progression on or After at Least One-line of Treatment (DESTINY-Lung05)
- Sponsor: AstraZeneca
- Enrolled: 72
- Outcomes: ICR-assessed ORR (Objective Response Rate): T-DXd Arm 56.9%; OS (Overall Survival): T-DXd Arm 21 months; ICR-assessed CNS-PFS (Central Nervous System Progression-free Survival): T-DXd Arm 15.5 months

## Sources

- ClinicalTrials.gov NCT05246514: https://clinicaltrials.gov/study/NCT05246514

## Connected records

- cancers: [HER2-mutant non-small-cell lung cancer](https://onco.cc/cancers/her2-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- key papers: [Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial](https://onco.cc/key-papers/paper-nct05246514-clin-lung-cancer-2026/)

---
JSON: https://onco.cc/api/v1/entities/nct05246514.json